Showing results (131-140 of 183) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.NPJ Breast Cancer|September 26, 2017
Video intervention increases participation of black breast cancer patients in therapeutic trialsBrandi N Robinson, Antoinette F Newman, Eshetu Tefera, et al.Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.Breast Cancer Research and Treatment|September 20, 2022
Molecular characterization of ESR1 variants in breast cancerArielle L Heeke, Andrew Elliott, Rebecca Feldman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.Journal of the National Cancer Institute|February 16, 2026
Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse eventsRakchha Chhetri, Natansh D Modi, Bradley D Menz, et al.Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.Pageof 19